PepEvolutionKPV
Alpha-MSH-derived NF-κB inhibitor studied for gut inflammation — very clean safety profile, limited human data.
Verdict — C · Emerging / Mixed
A genuinely interesting gut-inflammation and anti-inflammatory mechanism with an excellent safety profile — but the human data is very thin. A viable component in recovery stacks for the informed buyer; do not expect strong clinical validation.
Overview
KPV is a C-terminal tripeptide of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) that inhibits NF-κB signaling at picomolar concentrations in-vitro. Primarily studied for gut inflammation (IBD models) and wound healing, it has a small but growing body of in-vitro and animal evidence with very limited human clinical data. It is non-toxic by nature of its small endogenous-derived structure; the main risk is the thin evidence base rather than a safety signal.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.